SEC Form 4 · accession 0001209191-17-011305
Travere Therapeutics, Inc. · TVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William E. Rote
Officer — Senior Vice President, R&D
Period of report
Feb 13, 2017
Accepted (ET)
Feb 15, 2017 · 8:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001438533
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 13, 2017 | A | 10,000 | $0.00 | A | 10,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $20.61 | Feb 13, 2017 | A | 60,000 | A | — | Feb 12, 2027 | Common Stock | 60,000 | 60,000 | D |
Explanation of responses
- F1One fourth of the shares subject to the stock option shall vest and become exercisable on the first anniversary of the date of grant, and the remaining shares shall vest and become exercisable in twelve equal quarterly installments thereafter.